Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04900792 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
A Phase 1 study of Glioblastoma and Glioblastoma Multiforme, sponsored by Bryan Allen.
- Active
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT04900792: Active Phase 1 study of Glioblastoma and Glioblastoma Multiforme, sponsored by Bryan Allen.
NCT04900792 is a Phase 1 study of Glioblastoma and Glioblastoma Multiforme that is active but no longer recruiting, run by Bryan Allen. The registered enrollment target is 17 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04900792, a Phase 1 study of Glioblastoma and Glioblastoma Multiforme, is active but no longer recruiting, sponsored by Bryan Allen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial evaluates adding ferumoxytol and pharamcologic ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive ferumoxytol and pharmacologic ascorbate in addition to the standard treatment.
Primary Outcome
The recommended dose will be determined by incidence of dose limiting toxicities.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Ferumoxytol injection
- DRUG Pharmacological ascorbate
- RADIATION External beam radiation therapy
Study Locations (1)
Iowa
- Department of Radiation Oncology at University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What the registry record for NCT04900792 still lists
NCT04900792 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which Temozolomide is the first listed.
NCT04900792 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT04900792 about?
NCT04900792 is a clinical study titled "A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma". This clinical trial evaluates adding ferumoxytol and pharamcologic ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive ferumoxytol and pharmacologic ascorbate in addition to the standard treatment.
What is the current status of trial NCT04900792?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2023-02-28. Estimated completion is 2026-12-31.
What conditions does trial NCT04900792 study?
This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme.
What interventions are being tested in trial NCT04900792?
The interventions under investigation include: Temozolomide (DRUG), Ferumoxytol injection (DRUG), Pharmacological ascorbate (DRUG), External beam radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT04900792?
This trial is sponsored by Bryan Allen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04900792 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04900792's enrollment target sits among peer trials
17 166th of 199 higher than 31 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI